A	a	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
,	,	O	O	O	O
crossover	crossover	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
ephedrine	ephedrine	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
SSRI-induced	ssri-induced	O	O	O	O
female	female	O	O	O	O
sexual	sexual	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
objective	objective	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
whether	whether	O	O	O	O
ephedrine	ephedrine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
an	an	O	O	O	O
alpha-	alpha-	O	O	O	O
and	and	O	O	O	O
beta-adrenergic	beta-adrenergic	O	O	O	O
agonist	agonist	O	O	O	O
previously	previously	O	O	O	O
shown	shown	O	O	O	O
to	to	O	O	O	O
enhance	enhance	O	O	O	O
genital	genital	O	O	O	O
blood	blood	O	O	O	O
flow	flow	O	O	O	O
in	in	O	O	O	O
women	women	O	O	O	O
,	,	O	O	O	O
has	has	O	O	O	O
beneficial	beneficial	O	O	O	O
effects	effects	O	O	O	O
in	in	O	O	O	O
reversing	reversing	O	O	O	O
antidepressant-induced	antidepressant-induced	O	O	O	O
sexual	sexual	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Nineteen	nineteen	O	O	O	O
sexually	sexually	O	O	OTHERS	I
dysfunctional	dysfunctional	O	O	OTHERS	I
women	women	O	O	O	O
receiving	receiving	O	O	O	O
either	either	O	O	O	O
fluoxetine	fluoxetine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
sertraline	sertraline	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
or	or	O	O	O	O
paroxetine	paroxetine	CHEMICALS	O	OTHERS	I
participated	participated	O	O	O	O
in	in	O	O	O	O
an	an	O	O	O	O
eight-week	eight-week	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
,	,	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
,	,	O	O	O	O
cross-over	cross-over	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
ephedrine	ephedrine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
50	50	O	O	O	O
mg	mg	O	O	OTHERS	I
)	)	O	O	O	O
on	on	O	O	O	O
self-report	self-report	O	O	O	O
measures	measures	O	O	O	O
of	of	O	O	O	O
sexual	sexual	O	O	O	O
desire	desire	O	O	O	O
,	,	O	O	O	O
arousal	arousal	O	O	O	O
,	,	O	O	O	O
orgasm	orgasm	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
sexual	sexual	O	O	O	O
satisfaction	satisfaction	O	O	O	O
.	.	O	O	O	O

Although	although	O	O	O	O
there	there	O	O	O	O
were	were	O	O	O	O
significant	significant	O	O	O	O
improvements	improvements	O	O	O	O
relative	relative	O	O	O	O
to	to	O	O	O	O
baseline	baseline	O	O	O	O
in	in	O	O	O	O
sexual	sexual	O	O	O	O
desire	desire	O	O	O	O
and	and	O	O	O	O
orgasm	orgasm	O	O	O	O
intensity/pleasure	intensity/pleasure	O	O	O	O
on	on	O	O	O	O
50	50	O	O	O	O
mg	mg	O	O	OTHERS	I
ephedrine	ephedrine	CHEMICALS	O	OTHERS	I
1-hr	1-hr	O	O	O	O
prior	prior	O	O	O	O
to	to	O	O	O	O
sexual	sexual	O	O	O	O
activity	activity	O	O	O	O
,	,	O	O	O	O
significant	significant	O	O	O	O
improvements	improvements	O	O	O	O
in	in	O	O	O	O
these	these	O	O	O	O
measures	measures	O	O	O	O
,	,	O	O	O	O
as	as	O	O	O	O
well	well	O	O	O	O
as	as	O	O	O	O
in	in	O	O	O	O
sexual	sexual	O	O	O	O
arousal	arousal	O	O	O	O
and	and	O	O	O	O
orgasmic	orgasmic	O	O	O	O
ability	ability	O	O	O	O
also	also	O	O	O	O
were	were	O	O	O	O
noted	noted	O	O	O	O
with	with	O	O	O	O
placebo	placebo	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
findings	findings	O	O	O	O
highlight	highlight	O	O	O	O
the	the	O	O	O	O
importance	importance	O	O	O	O
of	of	O	O	O	O
conducting	conducting	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
trials	trials	O	O	O	O
for	for	O	O	O	O
this	this	O	O	O	O
condition	condition	O	O	O	O
.	.	O	O	O	O

